Table 1

Baseline characteristics in RA patients who were receiving MTX and comparison between patients with and without abnormal liver stiffness measurement (LSM)

All patients (n = 105)

LSM < 5.3 kPa(n = 81)

LSM > 5.3 kPa(n = 24)

P-value


Demographic variables

Age, years

54.0 (25, 73)

52.5 ± 10.3

52.3 ± 11.8

0.852

Male gender

20 (19.0)

16 (19.8)

4 (16.7)

0.736

Body mass index, kg/m2

22.1 (18.1, 27.6)

22.1 ± 2.5

22.3 ± 2.4

0.723

Metabolic syndrome, number patients (%)

6 (5.7)

3 (3.7)

3 (12.5)

0.105

Disease duration, weeks

140.4 (26.1, 739.2)

171.8 ± 123.9

240.5 ± 159

0.059

Laboratory variables

C-reactive protein, mg/L

1.2 (0, 124.0)

3.1 ± 5.7

6.9 ± 25.1

0.766

Erythrocyte sedimentation rate, mm/hr

33.0 (2, 111)

37.3 ± 22.3

32.4 ± 20.7

0.362

White blood cells, count/mm3

5,960.0 (2,390.0, 12,870.0)

6,355.9 ± 2,009.0

5,801.7 ± 1,853.9

0.319

Hemoglobin, g/dL

12.7 (9.9, 16.2)

12.7 ± 1.1

13.0 ± 1.0

0.324

Platelet count, × 1,000/mm3

241.0 (134.0, 470.0)

253.0 ± 60.3

250.8 ± 69.0

0.723

Prothrombin time, INR

0.9 (0.8, 1.2)

1.0 ± 0.1

1.0 ± 0.1

0.726

Glucose, mg/dL

85.0 (70.0, 125.0)

87.4 ± 10.7

86.4 ± 5.0

0.652

Blood urea nitrogen, mg/dL

14.4 (0.9, 28.1)

15.2 ± 4.8

14.1 ± 4.6

0.249

Creatinine mg/dL

0.7 (0.5, 1.3)

0.7 ± 0.2

0.7 ± 0.1

0.858

Uric acid, mg/dL

3.8 (1.5, 8.9)

4.0 ± 1.2

4.1 ± 1.8

0.582

Aspartate aminotransferase, IU/L

21.0 (13.0, 34.0)

21.9 ± 5.5

22.4 ± 6.8

0.881

Alanine aminotransferase, IU/L

17.0 (8.0, 39.0)

18.9 ± 7.7

19.0 ± 7.7

0.879

Total protein, mg/dL

6.9 (5.5, 7.9)

7.0 ± 0.4

7.0 ± 0.5

0.730

Serum albumin, mg/dL

4.3 (3.5, 4.9)

4.3 ± 0.3

4.2 ± 0.4

0.815

Total bilirubin, mg/dL

0.6 (0.2, 1.1)

0.6 ± 0.2

0.6 ± 0.2

0.461

Alkaline phosphatase, IU/L

52.0 (38.0, 110.0)

56.4 ± 17.0

54.7 ± 13.1

0.976

Gamma-glutamyltranspeptidase, IU/L

17.0 (5.0, 53.0)

22.6 ± 15.1

26.3 ± 19.1

0.340

Triglyceride, mg/dL

90.0 (26.0, 269.0)

108.9 ± 55.4

92.2 ± 41.4

0.197

High density cholesterol, mg/dL

55.0 (19.0, 86.0)

55.9 ± 10.4

53.2 ± 19.1

0.772

Low density cholesterol, mg/dL

105.4 (52.8, 172.6)

108.8 ± 26.8

107.4 ± 26.8

0.743

Cumulative dose of medication, mg

Methotrexate (105 patients)

2,032.5 (285.0, 7,800.0)

2,334.0 ± 1,939.9

3,127.9 ± 2,072.7

0.086

Leflunomide (53 patients)

7,800.0 (280.0, 38,520.0)

9,291.1 ± 9,331.8

19,919.3 ± 12,716.8

0.008

Sulfasalazine (82 patients)

360,000.0 (30,000.0, 6,028,000.0)

727,778.7 ± 969,150.7

1,093,547.6 ± 1,330,930.2

0.111

Hydroxychloroquine (65 patients)

94,600.0 (4,200.0, 868,000.0)

115,248.0 ± 120,975.1

182,013.3 ± 208,807.9

0.129

Prednisolone (89 patients)

3,015.0 (372.5, 20,212.5)

4,642.1.0 ± 4,196.7

6,756.7.1 ± 6,156.5

0.472

Meloxicam (90 patients)

6,273.8 (210.0, 2,895,000.0)

90,205.0 ± 363,930.2

161,274.6 ± 644,791.4

0.793

Celecoxib (70 patients)

163,000.0 (1,000.0, 1,503,000.0)

218,505.7 ± 253,487.6

316,705.9 ± 313,982.7

0.239

LSM

LSM, kPa, median (range)

4.4 (2.8, 17.8)

NA

NA

NA

LSM, kPa, median (IQR)

0.14 (0.02, 0.29)

NA

NA

NA

Success rate, %, median (IQR)

100.0 (63.0, 100.0)

NA

NA

NA


Values are expressed as median (range, IQR), number (%), or mean ± SD. INR, international normalized ratio; NA: not applicable.

Lee et al. Arthritis Research & Therapy 2012 14:R232   doi:10.1186/ar4075

Open Data